3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Subscribe To Our Newsletter & Stay Updated
